Development and validation of serological markers for detecting recent Plasmodium vivax infection

Longley, Rhea J., White, Michael T., Takashima, Eizo, Brewster, Jessica, Morita, Masayuki, Harbers, Matthias, Obadia, Thomas, Robinson, Leanne, Matsuura, Fumie, Liu, Zoe S.J., Li-Wai-Suen, Connie S.N, Tham, Wai-Hong, Healer, Julie, Huon, Christele, Chitnis, Chetan E., Nguitragool, Wang, Monteiro, Wuelton, Proietti, Carla, Doolan, Denise L., Siqueira, Andre M., Ding, Xavier C., Gonzalez, Iveth J., Kazura, James, Lacerda, Marcus, Sattabongkot, Jetsumom, Tsuboi, Takafumi, and Mueller, Ivo (2020) Development and validation of serological markers for detecting recent Plasmodium vivax infection. Nature Medicine, 26 (5). pp. 741-749.

[img] PDF (Published Version) - Published Version
Restricted to Repository staff only

View at Publisher Website: https://doi.org/10.1038/s41591-020-0841-...
 
7
2


Abstract

A major gap in the Plasmodium vivax elimination toolkit is the identification of individuals carrying clinically silent and undetectable liver-stage parasites, called hypnozoites. This study developed a panel of serological exposure markers capable of classifying individuals with recent P. vivax infections who have a high likelihood of harboring hypnozoites. We measured IgG antibody responses to 342 P. vivax proteins in longitudinal clinical cohorts conducted in Thailand and Brazil and identified candidate serological markers of exposure. Candidate markers were validated using samples from year-long observational cohorts conducted in Thailand, Brazil and the Solomon Islands and antibody responses to eight P. vivax proteins classified P. vivax infections in the previous 9 months with 80% sensitivity and specificity. Mathematical models demonstrate that a serological testing and treatment strategy could reduce P. vivax prevalence by 59-69%. These eight antibody responses can serve as a biomarker, identifying individuals who should be targeted with anti-hypnozoite therapy.

Item ID: 63899
Item Type: Article (Research - C1)
ISSN: 1546-170X
Copyright Information: © The Author(s), under exclusive licence to Springer Nature America, Inc. 2020
Funders: Global Health Innovative Technology Fund, National Institute of Allergy and Infectious Diseases (NIAID), National Health and Medical Research Council Australia (NHMRC), National Research Council of Thailand
Projects and Grants: NIAID National Institutes of Health grant 5R01 AI 104822, NIAID National Institutes of Health grant 5U19AI089686-06, NHMRC 1092789, NHMRC 1134989, NHMRC 1143187, NHMRC Independent Research Institute Infrastructure Support Scheme, NHMRC Senior Research Fellowship (1043345), NHMRC Principal Research Fellowship (1023636)
Date Deposited: 29 Jul 2020 07:38
FoR Codes: 32 BIOMEDICAL AND CLINICAL SCIENCES > 3207 Medical microbiology > 320704 Medical parasitology @ 33%
32 BIOMEDICAL AND CLINICAL SCIENCES > 3204 Immunology > 320405 Humoural immunology and immunochemistry @ 33%
31 BIOLOGICAL SCIENCES > 3101 Biochemistry and cell biology > 310114 Systems biology @ 34%
SEO Codes: 20 HEALTH > 2001 Clinical health > 200104 Prevention of human diseases and conditions @ 50%
20 HEALTH > 2001 Clinical health > 200101 Diagnosis of human diseases and conditions @ 50%
Downloads: Total: 2
Last 12 Months: 2
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page